Ignite Creation Date:
2024-05-05 @ 5:22 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00442650
Status:
COMPLETED
Last Update Posted:
2016-11-21
First Post:
2007-02-28
Brief Title:
Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis
Sponsor:
Merck KGaA Darmstadt Germany
Organization:
Merck KGaA Darmstadt Germany
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Moderate to Severe Psoriasis |
Keywords: